AORT
Artivion, Inc.
AORT has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over AORT overall, supported by stronger fundamentals and stronger modeled upside.
AORT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Weak |
AORT's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AORT PE Valuation
AORT has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
AORT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for AORT, with profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over AORT on the outlook, with more favorable profitability expectations.
AORT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.05 | — |
| Q3 2026 | -$0.35 | -$0.10 |
| Q2 2026 | -$0.06 | +$0.37 |
| Q1 2026 | $0.25 | +$0.76 |
| Q4 2025 | $0.21 | +$0.53 |
| Q3 2025 | -$0.25 | -$0.23 |
| Q2 2025 | -$0.43 | -$0.22 |
| Q1 2025 | -$0.51 | -$0.27 |
| Q4 2024 | -$0.32 | +$0.43 |
AORT is still losing money, but far less than before: $0.35 per share over the past year, against $1.03 at its worst in late 2022.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over AORT on earnings quality, reporting a profit while its opponent remains loss making.
AORT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $123.8M | +9.2% |
| Q2 2026 | $125.8M | +11% |
| Q1 2026 | $116.3M | +18% |
| Q4 2025 | $116M | +19% |
| Q3 2025 | $113.4M | +18% |
| Q2 2025 | $113M | +15% |
| Q1 2025 | $99M | +1.6% |
| Q4 2024 | $97.3M | +3.9% |
AORT's revenue has grown year over year for 23 quarters in a row: $124M last quarter, up 9.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.4% | -8.7 points |
| Q2 2026 | -6.7% | -14 points |
| Q1 2026 | 5% | +2.8 points |
| Q4 2025 | 9.2% | +6.5 points |
| Q3 2025 | 11% | +6.5 points |
| Q2 2025 | 7.4% | +0.8 points |
| Q1 2025 | 2.2% | -24 points |
| Q4 2024 | 2.7% | -0.6 points |
AORT's operating margin was 2.4% last quarter, down 8.7 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AORT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over AORT on profitability, with a higher operating margin.
AORT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17.6M | -200% |
| Q2 2026 | -$12M | -202% |
| Q1 2026 | -$6.8M | +$13.7M |
| Q4 2025 | -$7.9M | -191% |
| Q3 2025 | $17.7M | +126% |
| Q2 2025 | $11.7M | +224% |
| Q1 2025 | -$20.6M | -$11.5M |
| Q4 2024 | $8.7M | -2.2% |
AORT's free cash flow was −$44M over the past year, against $18M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AORT on cash generation, producing positive trailing cash flow while its opponent burns cash.
AORT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +177K shares |
| 1 year | -0.1% | -57K shares |
| 3 years | +19% | +7.8M shares |
| 5 years | +9.6% | +4.3M shares |
| Available history | +29% | +10.9M shares |
AORT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AORT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.5x | High |
| Q2 2026 | 6.3x | High |
| Q1 2026 | 2.6x | Moderate |
| Q4 2025 | 2.7x | Moderate |
| Q3 2025 | 2.9x | Moderate |
| Q2 2025 | 4.0x | Elevated |
| Q1 2025 | 7.0x | High |
| Q4 2024 | 4.1x | High |
AORT's net debt is about 8.5 years of its operating earnings (EBITDA), up from 2.9 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over AORT on leverage, with a lower net debt burden relative to earnings.
AORT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.0 | Neutral |
| Stochastic | 10.1 | Oversold |
AORT's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AORT PE vs Healthcare Sector
| Metric | AORT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AORT has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AORT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.7 | 11% below |
| 20 week MA | $24.2 | 20% below |
| 50 week MA | $30.8 | 37% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $25.7 | 24% below |
AORT is in a downtrend: it's below all five of its weekly moving averages, and 24% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AORT on trend strength, trading above more of its moving averages.
AORT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.7 | $23.5 | -12% |
| 2021 | $23.5 | $20.4 | -14% |
| 2022 | $20.4 | $11.8 | -42% |
| 2023 | $11.8 | $17.9 | +51% |
| 2024 | $17.9 | $29.0 | +62% |
| 2025 | $29.0 | $46.3 | +60% |
| 2026 YTD | $46.3 | $19.4 | -58% |
AORT has finished lower in three of the last six years. It's down 58% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AORT on returns for 2026, with the stronger performance.